Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.

The international journal of neuropsychopharmacology - 26 Nov 2020

Redenšek Sara, Jenko Bizjan Barbara, Trošt Maja, Dolžan Vita

Abstract excerpt

BACKGROUND: The most common psychiatric complications due to dopaminergic treatment in Parkinson's disease are visual hallucinations and impulse control disorders. Their development depends on clinical and genetic factors. METHODS: We evaluated the simultaneous effect of 16 clinical and 34 genetic variables on the occurrence of visual hallucinations and impulse control disorders. Altogether, 214 Parkinson's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Disruptive, Impulse Control, and Conduct Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Agents

Share to Hallucinations

Share to Parkinson Disease

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Source

Open in PubMed Open full text

Identifiers

PMID: 32710539
DOI: 10.1093/ijnp/pyaa028
PMCID: PMC7689202

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.PMID 32710539Read ↗

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's DiseaseSemantic proximity Read ↗

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?Semantic proximity Read ↗

Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease.Semantic proximity Read ↗

Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson’s DiseaseSemantic proximity Read ↗

Prediction of impulse control disorders in Parkinson’s disease: a longitudinal machine learning studySemantic proximity Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Risk prediction for complex diseases: application to Parkinson disease.Semantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.Semantic proximity Read ↗

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic StudiesSemantic proximity Read ↗

Dopamine genetic risk scores and psychiatric symptoms: Interacting risk factors for impulse control behaviours in de novo Parkinson's disease.Semantic proximity Read ↗

Integrating genetic and clinical data to predict impulse control disorders in Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.